Carfilzomib, cyclophosphamide and dexamethasone for newly diagnosed, high-risk myeloma patients not eligible for transplant: a pooled analysis of two studies

Despite remarkable advances in the treatment of multiple myeloma (MM) in the last decades, the prognosis of patients harboring highrisk cytogenetic abnormalities remains dismal as compared to that of standard-risk patients. Proteasome inhibitors have been demonstrated to partially ameliorate the pro...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Haematologica
Glavni autori: Mina, Roberto, Bonello, Francesca, Petrucci, Maria Teresa, Liberati, Anna Marina, Conticello, Concetta, Ballanti, Stelvio, Musto, Pellegrino, Olivieri, Attilio, Benevolo, Giulia, Capra, Andrea, Gilestro, Milena, Galieni, Piero, Cavo, Michele, Siniscalchi, Agostina, Palumbo, Antonio, Montefusco, Vittorio, Gaidano, Gianluca, Omedé, Paola, Boccadoro, Mario, Bringhen, Sara
Format: Artigo
Jezik:Inglês
Izdano: Fondazione Ferrata Storti 2020
Teme:
Article
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC8018137/
https://ncbi.nlm.nih.gov/pubmed/32107329
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3324/haematol.2019.243428
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items